Aneuploidy screening in the first trimester.
This article reviews the performance of first trimester screening for chromosomal anomalies using various combinations of ultrasound and maternal serum biochemical modalities. Detection rates in excess of 90% can be routinely achieved for Trisomy 21, Trisomy 13, Trisomy 18 using a combination of fetal nuchal translucency (NT) thickness and maternal serum free ss-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks of gestation.
Spencer
Kevin
K
Prenatal Screening Unit, Clinical Biochemistry Department, Harold Wood Hospital, Romford, UK. kevinspencer1@aol.com
D051722:ADAM Proteins / Q000097:blood; D000072199:ADAM12 Protein; D000782:Aneuploidy; D015415:Biomarkers / Q000097:blood; D004314:Down Syndrome / Q000175:diagnosis; D005260:Female; D005315:Fetal Diseases / Q000175:diagnosis*; D006801:Humans; D008565:Membrane Proteins / Q000097:blood; D048208:Nuchal Translucency Measurement; D011247:Pregnancy; D011261:Pregnancy Trimester, First; D011266:Pregnancy-Associated Plasma Protein-A; D011296:Prenatal Diagnosis; D016216:Ultrasonography, Prenatal
D015415:Biomarkers; D008565:Membrane Proteins; D051722:ADAM Proteins; D000072199:ADAM12 Protein; C000606480:ADAM12 protein, human; D011266:Pregnancy-Associated Plasma Protein-A